Pharmacotherapy for heart failure with left ventricular dysfunction: Beyond angiotensin-converting enzyme inhibitors and β-blockers

Pharmacotherapy

Volumn 28, Issue 7, 2008, Pages 920-931

  Norgard, Nicholas B ^a,b   Stark, Jennifer E ^a  

^a UNIVERSITY OF OKLAHOMA   (United States)

^b BCPS   (United States)

Author keywords

Additive therapies; Aldosterone antagonists; Angiotensin II receptor blockers; Heart failure; Isosorbide dinitrate plus hydralazine; Left ventricular dysfunction

Indexed keywords

ALDOSTERONE; ALDOSTERONE ANTAGONIST; ANGIOTENSIN II ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CANDESARTAN; CREATININE; DIGITALIS; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; EPLERENONE; HYDRALAZINE PLUS ISOSORBIDE DINITRATE; METOPROLOL; POTASSIUM; SPIRONOLACTONE; VALSARTAN;

ACUTE HEART INFARCTION; AFRICAN AMERICAN; CARDIOVASCULAR DISEASE; CARDIOVASCULAR SYSTEM; CREATININE BLOOD LEVEL; DISEASE SEVERITY; DIZZINESS; DRUG COST; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART AFTERLOAD; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HEART PRELOAD; HUMAN; HYPERKALEMIA; NONHUMAN; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; POTASSIUM BLOOD LEVEL; PRACTICE GUIDELINE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RETROSPECTIVE STUDY; REVIEW; SYSTOLIC DYSFUNCTION; THERAPY EFFECT; TIME SERIES ANALYSIS; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VASCULAR RESISTANCE;

ALDOSTERONE ANTAGONISTS; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; DRUG COMBINATIONS; HEART FAILURE; HUMANS; HYDRALAZINE; ISOSORBIDE DINITRATE; PRESCRIPTION FEES; RENIN-ANGIOTENSIN SYSTEM; VENTRICULAR DYSFUNCTION, LEFT;

EID: 45749105135     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.28.7.920     Document Type: Review

References (46)

1. Pagliaro P, Penna C. Rethinking the renin-angiotensin system and its role in cardiovascular regulation. Cardiovasc Drugs Ther 2005;19(1):77-87.
2. Willenbrock R, Philipp S, Mitrovic V, Dietz R. Neurohumoral blockade in CHF management. J Renin Angiotensin Aldosterone Syst 2000;1(suppl 1):24-30.
3. Berk BC. Angiotensin type 2 receptor (AT2R): a challenging twin. Sci STKE 2003;181:PE16.
4. de Gasparo M, Catt KJ, Inagami T, Wright JW, Unger T, for the International Union of Pharmacology, XXIII. The angiotensin II receptors. Pharmacol Rev 2000;52(3):415-72.
5. Rocha R, Stier CT Jr, Kifor I, et al. Aldosterone: a mediator of myocardial necrosis and renal arteriopathy. Endocrinology 2000;141:3871-8.
6. Weber KT, Sun Y, Campbell SE, et al. Chronic mineralocorticoid excess and cardiovascular remodeling. Steroids 1995,60:125-32.
7. Weber KT, Brilla CG. Pathological hypertrophy and cardiac interstitium: fibrosis and renin-angiotensin-aldosterone system. Circulation 1991;83:1849-65.
8. Brilla CG, Matsubara LS, Weber KT. Anti-aldosterone treatment and the prevention of myocardial fibrosis in primary and secondary hyperaldosteronism. J Mol Cell Cardiol 1993;25:563-75.
9. Struthers AD. Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in chronic heart failure. J Card Fail 1996;2:47-54.
10. McKelvie RS, Yusuf S, Pericak D, et al, for the RESOLVD Pilot Study Investigators. Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. Circulation 1999;100(10):1056-64.
11. van den Meiracker AH, Man in 't Veld AJ, Admiraal PJ, et al. Partial escape of angiotensin converting enzyme (ACE) inhibition during prolonged ACE inhibitor treatment: does it exist and does it affect the antihypertensive response? J Hypertens 1992;10(8):803-12.
12. Swedberg K, Eneroth P, Kjekshus J, Wilhelmsen L, for the CONSENSUS Trial Study Group. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. Circulation 1990;82(5):1730-6.
13. Weir MR, Dzau VJ. The renin-angiotensin-aldosterone system: a specific target for hypertension management. Am J Hypertens 1999;12(12 pt 3):205-13S.
14. Dzau VJ. Multiple pathways of angiotensin production in the blood vessel wall: evidence, possibilities and hypotheses. J Hypertens 1989;7(12):933-6.
15. Balcells E, Meng QC, Johnson WH Jr, Oparil S, Dell'Italia LJ. Angiotensin II formation from ACE and chymase in human and animal hearts: methods and species considerations. Am J Physiol 1997;273(4 pt 2):H1769-74.
16. Matsumoto T, Wada A, Tsutamoto T, Ohnishi M, Isono T, Kinoshita M. Chymase inhibition prevents cardiac fibrosis and improves diastolic dyslunction in the progression of heart failure. Circulation 2003;107(20):2555-8.
17. Roig E, Perez-Villa F, Morales M, et al. Clinical implications of increased plasma angiotensin II despite ACE inhibitor therapy in patients with congestive heart failure. Eur Heart J 2000;21(1):53-7.
18. Liu YH, Yang XP, Sharov VG, et al. Effects of angiotensin- converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure: role of kinins and angiotensin II type 2 receptors. J Clin Invest 1997;99(8): 1926-35.
19. Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial - the losartan heart failure survival study ELITE II. Lancet 2000;355(9215):1582-7.
20. Dickstein K, Kjekshus J. Comparison of the effects of losartan and captopril on mortality in patients after acute myocardial infarction: the OPTIMAAL trial design. Am J Cardiol 1999;83(4):477-81.
21. Pfeffer MA, McMurray JJV, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dyslunction, or both. N Engl J Med 2003;349(20):1893-906.
22. Cruden NL, Witherow FN, Webb DJ, Fox KA, Newby DE. Bradykinin contributes to the systemic hemodynamic effects of chronic angiotensin- converting enzyme inhibition in patients with heart failure. Arterioscler Thromb Vasc Biol 2004;24(6):1043-8.
23. Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001;345(23):1667-75.
24. McMurray JJ, Ostergren J, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting enzyme inhibitors: the CHARM-added trial. Lancet 2003;362(9386):767-71.
25. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Eng J Med 1991;325(5):293-302.
26. McMurray JJ, Young JB, Dunlap ME, et al. Relationship of dose of background angiotensin-converting enzyme inhibitor to the benefits of candesartan in the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM)-added trial. Am Heart J 2006;151(5):985-91.
27. Phillips CO, Kashani A, Ko DK, Francis G, Krumholz HM. Adverse effects of combination angiotensin II receptor blockers plus angiotensin-converting enzyme inhibitors for left ventricular dysfunction: a quantitative review of data from randomized clinical trials. Arch Intern Med 2007;167(18): 1930-6.
28. McKelvie RS, Rouleau JL, White M, et al. Comparative impact of enalapril, candesartan or metoprolol alone or in combination on ventricular remodeling in patients with congestive heart failure. Eur Heart J 2003;24(19):1727-34.
29. Hunt S, Abraham W, Chin M, et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American college of cardiology/American heart association task force on practice guidelines (writing committee to update the 2001 guidelines for the evaluation and management of heart failure): developed in collaboration with the American college of chest physicians and the international society for heart and lung transplantation: endorsed by the heart rhythm society [online exclusive article]. Circulation 2005;112(12):e154-235. Available from http://circ.ahajournals.org/cgi/content/full/112/12/e54.
30. Heart Failure Society of America. HFSA 2006 comprehensive heart failure practice guideline [online exclusive article]. J Card Fail 2006;12(1):e1-2. Available from http://www.onlinejcf.com/article/ PIIS1071916405013618/fulltext.
31. Dzau VJ, Colucci WS, Hollenberg NK, et al. Relation of the renin-angiotensin-aldosterone system to clinical state in congestive heart failure. Circulation 1981;63:645-51.
32. Wilke A, Funck R, Rupp H, Brilla CG. Effect of the renin-angiotensin-aldosterone system on the cardiac interstitium in heart failure. Basic Res Cardiol 1996;91:S79-84.
33. Rossi GP, Sacchetto A, Visentin P, et al. Changes in left ventricular anatomy and function in hypertension and primary aldosteronism. Hypertension 1996;27:1039-45.
34. Pitt B, Faiez Z, Remme W, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999;351:709-17.
35. Pitt B, Remme W, Faiez Z, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309-21.
36. Juurlink DN, Mamdani MM, Lee DS, et al. Rates of hyperkalemia after publication of the randomized aldactone evaluation study. N Engl J Med 2004;351:543-51.
37. Masoudi FA, Gross CP, Wang Y, et al. Adoption of spironolactone therapy for older patients with heart failure and left ventricular systolic dysfunction in the United States, 1998-2001. Circulation 2005;112:39-47.
38. Masoudi FA, Havranek EP, Wolfe P, et al. Most hospitalized older persons do not meet the enrollment criteria for clinical trials in heart failure. Am Heart J 2003;146:250-7.
39. Janssens S, Pokreisz P, Schoonjans L, et al. Cardiomyocyte- specific overexpression of nitric oxide synthase 3 improves left ventricular performance and reduces compensatory hypertrophy after myocardial infarction. Circ Res 2004;94:1256-62.
40. Loke KE, Laycock SK, Mital S, et al. Nitric oxide modulates mitochondrial respiration in failing human heart. Circulation 1999;100:1291-7.
41. Carson P, Ziesche S, Johnson G, Cohn JN, for the Vasodilator-Heart Failure Trial Study Group. Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials. J Card Fail 1999;5:178-87.
42. Cohn JN, Archibald DG, Ziesche S, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure: results of a veterans administration cooperative study. N Engl J Med 1986;314:1547-52.
43. Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991;325: 303-10.
44. Taylor AL, Ziesche S, Yancy C, et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med 2004;351:2049-57.
45. Rector RS, Cohn JN. Assessment of patient outcome with the Minnesota living with heart failure questionnaire: reliability and validity during a randomized, double-blind, placebo-controlled trial of pimobendan. Am Heart J 1992;124:1017-25.
46. Drugstore.com. Pricing information. Available from www.drugstore.com. Accessed June 18, 2007.